Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan vs Valsartan for Renal Protection in Peritoneal Dialysis
ChiCTR2100054733Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui University of Chinese Medicine
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan in end-stage kidney disease (ESKD), hypertension (HTN) and cardiac morbidity (2 arms), sponsored by First Affiliated Hospital of Anhui University of Chinese Medicine. Primary endpoint: Anuria at 24 months. Started Dec 2021; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
end-stage kidney disease (ESKD)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on ChiCTR2100054733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054733.